Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

VRG-50014 rescues ALS phenotypes in preclinical models

Dec. 12, 2019

CBDVHS demonstrates enhanced antiseizure activity compared to CBD

Dec. 12, 2019

EicOsis initiates phase I trial of sEH inhibitor EC-5026 for pain

Dec. 11, 2019

Implicit Bioscience presents phase I data for IC-14 in motor neuron disease

Dec. 11, 2019

Intrathecal AVXS-301 shows promise in preclinical models of ALS

Dec. 11, 2019

Quantitative and inducible modulation of the circadian clock with light using photocaged longdayisin

Dec. 10, 2019

The brain - silicone's new frontier?

Dec. 9, 2019

Sage Therapeutics reports topline data from pivotal phase III MOUNTAIN study

Dec. 9, 2019

Cytokinetics presents additional analysis data from FORTITUDE-ALS study

Dec. 9, 2019

NMDA receptor modulator NYX-458 begins phase II for MCI associated with Parkinson's disease

Dec. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...